Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Standard Biotools (LAB) Invested Capital (2016 - 2025)

Standard Biotools (LAB) has disclosed Invested Capital for 16 consecutive years, with $399.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Invested Capital fell 26.57% to $399.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was $399.7 million, a 26.57% decrease, with the full-year FY2024 number at $471.7 million, up 604.4% from a year prior.
  • Invested Capital was $399.7 million for Q3 2025 at Standard Biotools, down from $424.5 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $632.0 million in Q1 2024 to a low of -$126.7 million in Q3 2023.
  • A 5-year average of $179.7 million and a median of $99.3 million in 2021 define the central range for Invested Capital.
  • Peak YoY movement for Invested Capital: plummeted 492.62% in 2023, then skyrocketed 1159.91% in 2024.
  • Standard Biotools' Invested Capital stood at $95.2 million in 2021, then tumbled by 117.42% to -$16.6 million in 2022, then tumbled by 464.23% to -$93.5 million in 2023, then surged by 604.4% to $471.7 million in 2024, then dropped by 15.28% to $399.7 million in 2025.
  • Per Business Quant, the three most recent readings for LAB's Invested Capital are $399.7 million (Q3 2025), $424.5 million (Q2 2025), and $454.6 million (Q1 2025).